SeekingAlpha · Aug 13, 2026
Biofrontera Inc. (BFRI) Q2 2026 Earnings Call Transcript
Biofrontera Inc. (BFRI) Q2 2026 Earnings Call August 13, 2026 10:00 AM EDTCompany ParticipantsHermann Lubbert - CEO, President & ChairmanGeorge Jones -...
NASDAQ · BFRIW
Biofrontera Inc. Warrants
Healthcare · Drug Manufacturers - Specialty & Generic
$0.02
Up+$0.00 (+0.00%)
Updated Aug 15, 2026, 6:44 AM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 815.95K
- P/E ratio
- -0.45
- Dividend yield
- 0.00%
- 52-week range
- $0.02 – $0.28
- Volume
- 30.33K
- Avg. volume
- 8.86K
Price performance
BFRIW price history
1M range · 16 trading sessions · Daily adjusted prices
BFRIW closed at $0.02 after 16 trading sessions, up 23.27% for the selected period.
- Last close
- $0.02
- Period change
- +23.27%
- Period low
- $0.02
- Period high
- $0.04
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 14, 2026 | $0.025 | $0.025 | $0.0249 | $0.0249 | 30.33K |
| Aug 13, 2026 | $0.0249 | $0.0249 | $0.0249 | $0.0249 | 230 |
| Aug 12, 2026 | $0.0297 | $0.0297 | $0.0232 | $0.0233 | 768 |
| Aug 11, 2026 | $0.0297 | $0.0297 | $0.0296 | $0.0296 | 206 |
| Aug 10, 2026 | $0.0299 | $0.0299 | $0.0232 | $0.0232 | 1.3K |
| Aug 7, 2026 | $0.0232 | $0.0299 | $0.0232 | $0.0299 | 383 |
| Aug 5, 2026 | $0.0232 | $0.0279 | $0.0232 | $0.0279 | 6.25K |
| Aug 3, 2026 | $0.0266 | $0.0266 | $0.0266 | $0.0266 | 250 |
| Jul 30, 2026 | $0.03 | $0.03 | $0.03 | $0.03 | 6.81K |
| Jul 29, 2026 | $0.0349 | $0.0349 | $0.0349 | $0.0349 | 2.01K |
| Jul 27, 2026 | $0.025 | $0.025 | $0.025 | $0.025 | 306 |
| Jul 24, 2026 | $0.035 | $0.035 | $0.035 | $0.035 | 407 |
| Jul 23, 2026 | $0.035 | $0.035 | $0.0231 | $0.0231 | 1.78K |
| Jul 22, 2026 | $0.035 | $0.035 | $0.0201 | $0.0285 | 2.58K |
| Jul 21, 2026 | $0.036 | $0.036 | $0.0343 | $0.0359 | 1.98K |
| Jul 17, 2026 | $0.0222 | $0.0222 | $0.0201 | $0.0202 | 52.18K |
Latest BFRIW news
The latest Smart Investors Daily articles mentioning BFRIW.
Stock researchCompany · Overview
BFRIW research
Overview
Company profile and research snapshot.
Company profile
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
SeekingAlpha · Jun 11, 2026
Biofrontera Inc. (BFRI) Shareholder/Analyst Call Prepared Remarks Transcript
Biofrontera Inc. (BFRI) Shareholder/Analyst Call June 11, 2026 10:00 AM EDTCompany ParticipantsHermann Lubbert - CEO, President &...
GlobeNewswire Inc. · Dec 4, 2025
Last Patient Completes Biofrontera’s Phase 1 Pharmacokinetics Study of Ameluz® for Treatment of Actinic Keratoses on the Trunk and Extremities
Biofrontera completed its Phase 1 pharmacokinetic study for Ameluz® to expand treatment of actinic keratoses to neck, trunk, and extremities, with plans to submit a supplemental New Drug Application to the FDA in summer 2026.
The Motley Fool · Aug 14, 2025
Biofrontera Q2 Revenue Jumps 15%
Biofrontera reported a 15% revenue increase in Q2 2025, with record Ameluz sales and strategic shifts towards a royalty model. The company is advancing clinical trials for label expansions in actinic keratosis and basal cell carcinoma treatments.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
